|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5716826A
(en)
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6641809B1
(en)
|
1990-03-26 |
2003-11-04 |
Bristol-Myers Squibb Company |
Method of regulating cellular processes mediated by B7 and CD28
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
ATE248924T1
(de)
|
1991-05-06 |
2003-09-15 |
Us Gov Health & Human Serv |
Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US6887471B1
(en)
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US20020159979A1
(en)
|
1994-06-06 |
2002-10-31 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US6361770B1
(en)
|
1994-09-23 |
2002-03-26 |
University Of British Columbia |
Method of enhancing expression of MHC class I molecules bearing endogenous peptides
|
|
ES2154738T3
(es)
|
1994-10-03 |
2001-04-16 |
Us Gov Health & Human Serv |
Composicion que comprende un virus recombinante que expresa un antigeno y un virus recombinante que expresa una molecula inmunoestimuladora.
|
|
US5998205A
(en)
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7153510B1
(en)
|
1995-05-04 |
2006-12-26 |
Yale University |
Recombinant vesiculoviruses and their uses
|
|
US5767071A
(en)
|
1995-06-07 |
1998-06-16 |
Ixsys Incorporated |
Sevenmer cyclic peptide inhibitors of diseases involving αv β3
|
|
US5780426A
(en)
|
1995-06-07 |
1998-07-14 |
Ixsys, Incorporated |
Fivemer cyclic peptide inhibitors of diseases involving αv β3
|
|
FR2735789B1
(fr)
|
1995-06-23 |
1997-07-25 |
Centre Nat Rech Scient |
Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
|
|
CA2230758A1
(en)
|
1995-09-08 |
1997-03-13 |
Genzyme Corporation |
Improved aav vectors for gene therapy
|
|
US7001765B2
(en)
|
1996-03-06 |
2006-02-21 |
Medigene Ag |
Adeno-associated virus vector for boosting immunogenicity of cells
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
CA2300957A1
(en)
|
1997-08-15 |
1999-02-25 |
Rubicon Laboratory, Inc. |
Retrovirus and viral vectors
|
|
EP1015619A1
(en)
|
1997-09-19 |
2000-07-05 |
The Trustees Of The University Of Pennsylvania |
Methods and cell line useful for production of recombinant adeno-associated viruses
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6436392B1
(en)
|
1998-05-20 |
2002-08-20 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors
|
|
US20040063094A1
(en)
|
1998-05-20 |
2004-04-01 |
Biovex Limited |
Mutant herpes simplex viruses and uses thereof
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
JP2002522451A
(ja)
|
1998-08-07 |
2002-07-23 |
ユニバーシティ オブ ワシントン |
免疫学的単純ヘルペスウイルス抗原とその使用法
|
|
ATE454445T1
(de)
|
1998-11-10 |
2010-01-15 |
Univ North Carolina |
Virusvektoren und verfahren für ihre herstellung und verabreichung.
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
GB9904582D0
(en)
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
|
US6428968B1
(en)
|
1999-03-15 |
2002-08-06 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
|
DE19933288A1
(de)
|
1999-07-15 |
2001-01-18 |
Medigene Ag |
Strukturprotein von Adeno-assoziiertem Virus mit veränderter Antigenität, seine Herstellung und Verwendung
|
|
US6365619B1
(en)
|
1999-07-22 |
2002-04-02 |
Novartis Ag |
Treatment of arteriosclerosis
|
|
ATE403715T1
(de)
|
1999-08-09 |
2008-08-15 |
Targeted Genetics Corp |
Erhöhung der expression einer einzelsträngigen, heterologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
|
|
EP1218504B1
(en)
|
1999-09-21 |
2007-07-11 |
Genetics Institute, LLC |
Gl50 molecules and uses therefor
|
|
US7241447B1
(en)
|
1999-10-07 |
2007-07-10 |
University Of Iowa Research Foundation |
Adeno-associated virus vectors and uses thereof
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
EP1242116A2
(en)
|
1999-12-22 |
2002-09-25 |
Onyx Pharmaceuticals, Inc. |
Herpes simplex virus-1 glycoprotein c mutants for treating unwanted hyperproliferative cell growth
|
|
PT1252322E
(pt)
|
2000-01-21 |
2005-03-31 |
Biovex Ltd |
Estirpes de virus de herpes para terapia genica
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
US7094875B2
(en)
|
2000-06-23 |
2006-08-22 |
Maxygen, Inc. |
Co-stimulatory polypeptides
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
AU7309601A
(en)
|
2000-06-28 |
2002-01-08 |
Genetics Inst |
Pd-l2 molecules: novel pd-1 ligands and uses therefor
|
|
US7011972B2
(en)
|
2000-07-18 |
2006-03-14 |
The Scripps Research Institute |
Fusion polypeptide comprising two ligand binding domains
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
US6653103B2
(en)
|
2001-03-30 |
2003-11-25 |
Wisconsin Alumni Research Foundation |
Inhibition of nucleocytoplasmic transport by vesicular stomatitis virus M protein-like polypeptides
|
|
MXPA03010278A
(es)
|
2001-05-11 |
2004-12-06 |
Wellstat Biologics Corp |
Terapia con virus oncolitico.
|
|
NZ530451A
(en)
|
2001-06-29 |
2008-04-30 |
Univ Leland Stanford Junior |
TIM gene sequences and their use in immunological disorders and cancer
|
|
EP1411880B1
(en)
|
2001-07-11 |
2018-04-25 |
University of Miami |
Recombinant vsv for the treatment of tumor cells
|
|
CN1304559C
(zh)
|
2001-10-09 |
2007-03-14 |
杭州康科生物技术有限公司 |
表达热休克蛋白的溶瘤微生物及其应用
|
|
ATE454447T1
(de)
|
2001-11-30 |
2010-01-15 |
Us Gov Health & Human Serv |
Peptidagonisten für prostata-spezifisches antigen und ihre verwendung
|
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
|
CA2479763A1
(en)
|
2002-03-27 |
2003-10-09 |
Baylor College Of Medicine |
Potent oncolytic herpes simplex virus for cancer therapy
|
|
US8535672B2
(en)
|
2002-04-04 |
2013-09-17 |
Yissum Research Development Of The Hebrew University Of Jerusalem |
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
|
|
US20030225260A1
(en)
|
2002-04-30 |
2003-12-04 |
Snyder Richard O. |
Production of recombinant AAV virions
|
|
CA2489523A1
(en)
|
2002-06-21 |
2003-12-31 |
Wellstat Biologics Corporation |
Administration of therapeutic viruses
|
|
EP1391213A1
(en)
|
2002-08-21 |
2004-02-25 |
Boehringer Ingelheim International GmbH |
Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
|
|
WO2004022716A2
(en)
|
2002-09-09 |
2004-03-18 |
University Of Tennessee Research Foundation |
Recombinatant mutants of rhabdovirus and methods of use thereof
|
|
EP1553966B1
(en)
|
2002-10-03 |
2012-08-01 |
Wyeth Holdings Corporation |
Fusion peptides comprising the human papillomavirus e7 and e6 polypeptides and immunogenic compositions thereof
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
ES2347241T3
(es)
|
2002-12-16 |
2010-10-27 |
Genentech, Inc. |
Variantes de inmunoglobulina y sus utilizaciones.
|
|
US7731974B2
(en)
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
EP1606411B1
(en)
|
2003-03-27 |
2008-12-10 |
Ottawa Health Research Institute |
Mutant vesicular stomatitis viruses and use thereof
|
|
RU2376371C2
(ru)
|
2003-06-18 |
2009-12-20 |
Дженелюкс Корпорейшн |
Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
|
|
DK3211085T3
(da)
|
2003-09-30 |
2021-06-21 |
Univ Pennsylvania |
Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
|
|
GB0326798D0
(en)
|
2003-11-17 |
2003-12-24 |
Crusade Lab Ltd |
Methods for generating mutant virus
|
|
JP2007511216A
(ja)
|
2003-11-17 |
2007-05-10 |
クルセイド ラボラトリーズ リミテッド |
変異ウイルス
|
|
US7897146B2
(en)
|
2003-11-17 |
2011-03-01 |
Crusade Laboratories Limited |
Treatment using herpes simplex virus
|
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
CN1942483B
(zh)
|
2004-04-13 |
2012-09-26 |
弗·哈夫曼-拉罗切有限公司 |
抗p型选凝素抗体
|
|
WO2005116224A2
(en)
|
2004-05-18 |
2005-12-08 |
Children's Memorial Hospital |
Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
|
|
US7427396B2
(en)
|
2004-06-03 |
2008-09-23 |
Genzyme Corporation |
AAV vectors for gene delivery to the lung
|
|
WO2006002394A2
(en)
|
2004-06-24 |
2006-01-05 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
WO2006033386A1
(ja)
|
2004-09-22 |
2006-03-30 |
Kirin Beer Kabushiki Kaisha |
安定化されたヒトIgG4抗体
|
|
US20100111856A1
(en)
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
|
US20090208924A1
(en)
|
2004-12-01 |
2009-08-20 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of Replication Competent Viruses for Therapeutic Use
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
EP1885186B1
(en)
|
2005-06-01 |
2015-09-02 |
California Institute Of Technology |
Method of targeted gene delivery using viral vectors
|
|
CN105483093A
(zh)
|
2005-06-23 |
2016-04-13 |
休斯顿大学 |
Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途
|
|
SG196835A1
(en)
|
2005-07-18 |
2014-02-13 |
Amgen Inc |
Human anti-b7rp1 neutralizing antibodies
|
|
US7943374B2
(en)
|
2005-08-21 |
2011-05-17 |
Markus Hildinger |
Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
|
|
GB0522476D0
(en)
|
2005-11-03 |
2005-12-14 |
Biovex Ltd |
Oncolytic herpes virus vectors
|
|
AU2007275010B2
(en)
|
2006-07-21 |
2013-06-20 |
California Institute Of Technology |
Targeted gene delivery for dendritic cell vaccination
|
|
WO2008100292A2
(en)
|
2006-10-16 |
2008-08-21 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
US8907065B2
(en)
|
2006-12-15 |
2014-12-09 |
Ablynx N.V. |
Polypeptides that modulate the interaction between cells of the immune system
|
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
WO2008099189A2
(en)
|
2007-02-16 |
2008-08-21 |
Crusade Laboratories Limited |
Herpes simplex viruses and methods of viral replication
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
CN101784564B
(zh)
|
2007-07-13 |
2014-07-02 |
约翰霍普金斯大学 |
B7-dc变体
|
|
EP2173368A1
(en)
|
2007-07-18 |
2010-04-14 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
DK3059246T3
(en)
|
2007-09-26 |
2018-10-01 |
Chugai Pharmaceutical Co Ltd |
Modified constant region of an antibody
|
|
WO2009054996A2
(en)
|
2007-10-25 |
2009-04-30 |
Genelux Corporation |
Systems and methods for viral therapy
|
|
EP2225277A4
(en)
|
2007-11-27 |
2012-03-14 |
Viventia Biotech Inc |
ANTIBODIES TO A CANCER-ASSOCIATED EPITOPE OF THE VARIANT NFKBIB AND APPLICATIONS THEREOF
|
|
EP2222861B1
(en)
|
2007-12-11 |
2017-12-06 |
The University of North Carolina At Chapel Hill |
Polypurine tract modified retroviral vectors
|
|
US11260133B2
(en)
|
2008-02-21 |
2022-03-01 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to peptides and proteins with C-terminal elements
|
|
US8313896B2
(en)
|
2008-04-04 |
2012-11-20 |
The General Hospital Corporation |
Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
|
|
US20120052003A9
(en)
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
EP2307033A4
(en)
|
2008-05-29 |
2012-06-13 |
Gen Hospital Corp |
USE OF ONCOLYTIC HERPESVIRUS FOR THE KILLING OF CANCER STEM CELLS
|
|
EP2328920A2
(en)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
|
EP2398466B1
(en)
|
2008-11-24 |
2021-02-17 |
Massachusetts Institute of Technology |
Methods and compositions for localized nanoparticle delivery to a tumor
|
|
US8481297B2
(en)
|
2009-01-08 |
2013-07-09 |
Yale University |
Compositions and methods of use of an oncolytic vesicular stomatitis virus
|
|
US20150359909A1
(en)
|
2009-07-16 |
2015-12-17 |
University College Cork-National University Of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
EP2283810A1
(en)
|
2009-07-16 |
2011-02-16 |
University College Cork-National University of Ireland, Cork |
Orally administered bacteria as vehicles for systemic delivery of agents
|
|
HRP20140327T4
(hr)
|
2009-07-24 |
2017-11-03 |
Immune Design Corp |
Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
|
|
US8840889B2
(en)
|
2009-08-13 |
2014-09-23 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
WO2011097477A1
(en)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
US8642557B2
(en)
|
2010-03-12 |
2014-02-04 |
Abbvie Biotherapeutics Inc. |
CTLA4 proteins and their uses
|
|
US9637557B2
(en)
|
2010-04-23 |
2017-05-02 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
|
CN107090029B
(zh)
|
2010-11-11 |
2021-07-13 |
港大科桥有限公司 |
可溶性 pd-1变体、融合构建体及其用途
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
ES2668895T3
(es)
|
2011-03-16 |
2018-05-23 |
Amgen Inc. |
Variantes de Fc
|
|
EP3632463A1
(en)
|
2011-04-08 |
2020-04-08 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
KR20140029446A
(ko)
|
2011-04-15 |
2014-03-10 |
컴퓨젠 엘티디. |
면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
CN107519486B
(zh)
|
2011-06-24 |
2021-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
WO2013001517A1
(en)
*
|
2011-06-30 |
2013-01-03 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
CN107988156B
(zh)
|
2011-06-30 |
2022-01-04 |
建新公司 |
T细胞活化的抑制剂
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
JP2015512263A
(ja)
|
2012-03-30 |
2015-04-27 |
イミューン デザイン コーポレイション |
Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子
|
|
WO2013156054A1
(en)
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
|
KR102133060B1
(ko)
|
2012-05-11 |
2020-07-10 |
메디뮨 리미티드 |
Ｃｔｌａ－４ 변이체
|
|
WO2014089113A1
(en)
*
|
2012-12-03 |
2014-06-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
|
KR20150090919A
(ko)
|
2012-12-04 |
2015-08-06 |
온코메드 파마슈티칼스, 인크. |
결합제를 사용한 면역요법
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
EA201591806A1
(ru)
|
2013-03-15 |
2016-01-29 |
Байоджен Ма Инк. |
Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
|
|
JP6616284B2
(ja)
|
2013-04-23 |
2019-12-04 |
ザ ユニバーシティ コート オブ ザ ユニバーシティ オブ アバディーン |
特異的結合分子の人工ライブラリー
|
|
WO2014198002A1
(en)
|
2013-06-14 |
2014-12-18 |
Ottawa Hospital Research Institute |
A bacterium producing an interferon binding protein and uses thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
US20160271218A1
(en)
|
2013-06-27 |
2016-09-22 |
Mor Research Applications Ltd. |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
WO2015103438A2
(en)
|
2014-01-02 |
2015-07-09 |
Genelux Corporation |
Oncolytic virus adjunct therapy with agents that increase virus infectivity
|
|
WO2015107026A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
|
EP3105333B1
(en)
|
2014-02-10 |
2020-04-08 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
KR102497443B1
(ko)
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
US20170196954A1
(en)
|
2014-07-15 |
2017-07-13 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
DK3552615T3
(da)
|
2014-07-16 |
2022-02-14 |
Transgene |
Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
|
|
HRP20201153T1
(hr)
|
2014-08-08 |
2021-01-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Pd-1 sredstva visokog afiniteta i načini uporabe
|
|
KR102812180B1
(ko)
|
2014-09-03 |
2025-05-23 |
버베리안 노딕 에이/에스 |
재조합 변형된 백시니아 바이러스 앙카라 (mva) 필로바이러스 백신
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
AU2015343048A1
(en)
|
2014-11-06 |
2017-05-18 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
|
EP3020816A1
(en)
|
2014-11-11 |
2016-05-18 |
University College Cork |
Bacterial mediated gene therapy
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
JP6841812B2
(ja)
|
2015-04-02 |
2021-03-10 |
キャンキュア リミティド |
免疫応答を惹起するための作用物質及び組成物
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
EP3283508B1
(en)
*
|
2015-04-17 |
2021-03-17 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins with tunable affinities
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
HUE055207T2
(hu)
|
2015-07-30 |
2021-11-29 |
Macrogenics Inc |
PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
|
|
AU2016303485A1
(en)
|
2015-07-31 |
2018-03-01 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
CA2993429A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
AU2016323069A1
(en)
|
2015-09-14 |
2018-04-12 |
Alpine Immune Sciences, Inc. |
Tunable variant immunoglobulin superfamily domains and engineered cell therapy
|
|
SG10201912943RA
(en)
|
2015-10-02 |
2020-02-27 |
Symphogen As |
Anti-pd-1 antibodies and compositions
|
|
TWI705972B
(zh)
|
2015-11-04 |
2020-10-01 |
臺北榮民總醫院 |
惡性病變的組合治療
|
|
EA201891178A1
(ru)
|
2015-12-14 |
2019-01-31 |
Макродженикс, Инк. |
Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
|
|
US11078282B2
(en)
|
2016-04-15 |
2021-08-03 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
|
SG11201808457PA
(en)
|
2016-04-15 |
2018-10-30 |
Alpine Immune Sciences Inc |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
US11339201B2
(en)
|
2016-05-18 |
2022-05-24 |
Albert Einstein College Of Medicine |
Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
EP3529361B1
(en)
|
2016-10-20 |
2021-03-24 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
KR102692556B1
(ko)
|
2017-03-16 |
2024-08-09 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 변이체 면역조절 단백질 및 그의 용도
|
|
PT3697810T
(pt)
|
2017-10-18 |
2026-02-19 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
|
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
JP2022529059A
(ja)
|
2019-04-17 |
2022-06-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用
|